PDF herunterladen
Aktuelle Neurologie 2005; 32(4): 208-216
DOI: 10.1055/s-2004-828401
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Cannabinoide bei multipler Sklerose?

Cannabinoids and Multiple SclerosisS.  Schwarz1 , H.  Leweling2 , B.-U.  Sagstetter3 , H.-M.  Meinck4
  • 1Neurologische Klinik, Klinikum Mannheim der Universität Heidelberg, Mannheim
  • 2Medizinische Klinik, Klinikum Mannheim der Universität Heidelberg, Mannheim
  • 3Apotheke, Klinikum Mannheim der Universität Heidelberg, Mannheim
  • 4Neurologische Klinik, Klinikum Heidelberg der Universität Heidelberg
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
04. Mai 2005 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Cannabinoide werden von vielen Patienten mit MS als alternative Therapie von Spastik und Schmerzen angewendet. Pathophysiologische Überlegungen, experimentelle Ergebnisse, Fallberichte sowie kleine Fallserien deuten in der Tat günstige Effekte von Cannabinoiden auf diese Symptome an. Allerdings fanden neuere kontrollierte Studien keinen positiven Effekt auf die Spastik. Viele Patienten erleben subjektiv eine Symptombesserung unter Cannabinoiden, auch wenn die objektiven Parameter unverändert bleiben. Gravierende Nebenwirkungen von Cannabinoiden sind selten. Darüber hinaus könnten sich Cannabinoide aufgrund immunmodulatorischer Effekte günstig auf den Krankheitsverlauf der MS auswirken; klinische Daten hierzu liegen noch nicht vor. Zur Behandlung der MS gibt es derzeit kein zugelassenes Fertigarzneimittel, das Cannabinoide enthält. Solange nicht valide Daten aus prospektiven Studien vorliegen, kann der Einsatz von Cannabinoiden bei MS nicht empfohlen werden. Im Einzelfall und bei Symptomen, die auf übliche Maßnahmen nicht ansprechen, kann ein experimenteller Therapieversuch nach Protokoll mit Cannabinoiden gerechtfertigt sein.

Abstract

Many patients with MS consider cannabinoids as an alternative treatment for spasticity, pain, and other MS symptoms. Pathophysiological considerations, animal experiments, single case reports and a few small case series indicate indeed that cannabinoids may improve these symptoms. However, recent controlled clinical trials do not support this view. Many patients report subjective improvement after cannabinoids, even if the objective parameters remain unchanged. Serious side effects of cannabinoids are uncommon. Because of immunomodulatory properties; cannabinoids might positively influence the course of the disease. However, there are no clinical studies on the long-term effects of cannabinoids in MS. Cannabinoids cannot be recommended for general use in MS patients until reliable data from clinical trials is available. In selected patients with symptoms refractory to conventional treatment, an experimental therapy with cannabinoids may be justified.

Literatur

  • 1 Henze T, Toyka K V. Therapie von MS-Symptomen. Auch hier sind Leitlinien notwendig.  Nervenarzt. 2004;  75 (suppl 1) S1
    CrossrefPubMedGoogle Scholar
  • 2 Paty D W, Ebers G C. Multiple sclerosis. Philadelphia; FA Davis 1998
    Google Scholar
  • 3 Paisley S, Beard S, Hunn A, Wight J. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review.  Mult Scler. 2002;  8 319-329
    CrossrefPubMedGoogle Scholar
  • 4 Schapiro R T. Pharmacologic options for the management of multiple sclerosis symptoms.  Neurorehabil Neural Repair. 2002;  16 223-231
    CrossrefPubMedGoogle Scholar
  • 5 Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) . Symptomatische Therapie der Multiplen Sklerose.  Nervenarzt. 2004;  75 (suppl 1) S2-S39
    PubMedGoogle Scholar
  • 6 Shakespeare D, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003 4 CD001332
    Google Scholar
  • 7 Ivanhoe C B, Tilton A H, Francisco G E. Intrathecal baclofen therapy for spastic hypertonia.  Phys Med Rehabil Clin N Am. 2001;  12 923-938, viii-ix
    PubMedGoogle Scholar
  • 8 Ochs G, Reimann I W. Baclofen intrathekal. Stuttgart, New York; Thieme 1995
    Google Scholar
  • 9 Alusi S H, Glickman S, Aziz T Z, Bain P G. A study of tremor in multiple sclerosis.  Brain. 2001;  124 720-730
    CrossrefPubMedGoogle Scholar
  • 10 Schurman P R, Bosch D A, Bossuyt P M. et al . A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor.  N Engl J Med. 2000;  342 461-468
    CrossrefPubMedGoogle Scholar
  • 11 Somerset M, Campbell R, Sharp D J, Peters T J. What do people with MS want and expect from health-care services?.  Health Expect. 2001;  4 29-37
    CrossrefPubMedGoogle Scholar
  • 12 Health Canada. Office of Cannabis Medical Access .http://http: //www.hc-sc.gc.ca/hecs-sesc/ocma/info.htm . Accessed 20.5.2004
  • 13 Page S A, Verhoef M J, Stebbins R A. et al . Cannabis use as described by people with multiple sclerosis.  Can J Neurol Sci. 2003;  30 201-205
    PubMedGoogle Scholar
  • 14 Clark A J, Ware M A, Yazer E. et al . Patterns of cannabis use among patients with multiple sclerosis.  Neurology. 2004;  62 2098-2100
    CrossrefPubMedGoogle Scholar
  • 15 Consroe P, Musty R, Rein J. et al . The perceived effects of smoked cannabis on patients with multiple sclerosis.  Eur Neurol. 1997;  38 44-48
    PubMedGoogle Scholar
  • 16 Page S A, Verhoef M J, Stebbins R A. et al . The use of complementary and alternative therapies by people with multiple sclerosis.  Chronic Dis Can. 2003;  24 75-79
    PubMedGoogle Scholar
  • 17 Kalant H. Medicinal use of cannabis: history and current status.  Pain Res Manag. 2001;  6 80-91
    PubMedGoogle Scholar
  • 18 Mechoulam R. The pharmacohistory of cannabis. In: Mechoulam R (ed) Cannabinoids as Therapeutic Agents. Boca Raton; CRC Press 1986: 1-19
    Google Scholar
  • 19 Ashton C H. Pharmacology and effects of cannabis: a brief review.  Br J Psychiatry. 2001;  178 101-106
    CrossrefPubMedGoogle Scholar
  • 20 Askew W E, Ho B T. Effects of tetrahydrocannabinols on cyclic AMP levels in rat brain areas.  Experientia. 1974;  30 879-880
    PubMedGoogle Scholar
  • 21 Matsuda L A, Lolait S J, Brownstein M J. et al . Structure of a cannabinoid receptor and functional expression of the cloned cDNA.  Nature. 1990;  346 561-564
    CrossrefPubMedGoogle Scholar
  • 22 Munro S, Thomas K L, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids.  Nature. 1993;  365 61-65
    CrossrefPubMedGoogle Scholar
  • 23 Petrocellis L D De, Cascio M G, Marzo V D. The endocannabinoid system: a general view and latest additions.  Br J Pharmacol. 2004;  141 765-774
    CrossrefPubMedGoogle Scholar
  • 24 Landfield P W, Eldridge J C. Neurotoxicity and drugs of abuse: cannabinoid interaction with brain glucocorticoid receptors.  NIDA Res Monogr. 1993;  136 242-256
    PubMedGoogle Scholar
  • 25 Herkenham M, Lynn A B, Little M D. et al . Cannabinoid receptor localization in brain.  Proc Natl Acad Sci U S A. 1990;  87 1932-1936
    CrossrefPubMedGoogle Scholar
  • 26 Mailleux P, Parmentier M, Vanderhaeghen J J. Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides.  Neurosci Lett. 1992;  143 200-204
    CrossrefPubMedGoogle Scholar
  • 27 Freund T F, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling.  Physiol Rev. 2003;  83 1017-1066
    PubMedGoogle Scholar
  • 28 Monory K, Tzavara E T, Lexime J. et al . Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice.  Biochem Biophys Res Commun. 2002;  292 231-235
    CrossrefPubMedGoogle Scholar
  • 29 Iversen L. Cannabis and the brain.  Brain. 2003;  126 1252-1270
    Google Scholar
  • 30 Rodriguez de Fonseca F, Arco I Del, Martin-Calderon J L. et al . Role of the endogenous cannabinoid system in the regulation of motor activity.  Neurobiol Dis. 1998;  5 483-501
    CrossrefPubMedGoogle Scholar
  • 31 Mechoulam R, Fride E. Physiology. A hunger for cannabinoids.  Nature. 2001;  410 763, 765
    PubMedGoogle Scholar
  • 32 Fernandez J R, Allison D B. Rimonabant Sanofi-Synthélabo.  Curr Opin Investig Drugs. 2004;  5 430-435
    PubMedGoogle Scholar
  • 33 Agurell S, Halldin M, Lindgren J E. et al . Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man.  Pharmacol Rev. 1986;  38 21-43
    PubMedGoogle Scholar
  • 34 Huestis M A, Sampson A H, Holicky B J. et al . Characterization of the absorption phase of marijuana smoking.  Clin Pharmacol Ther. 1992;  52 31-41
    PubMedGoogle Scholar
  • 35 Uhlenbrock S, Langebrake C. Cannabis. Von der Hippie-Droge zum Medikament. Pharmazeutische Zeitung 2002
    Google Scholar
  • 36 Agurell S, Leander K. Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking.  Acta Pharm Suec. 1971;  8 391-402
    PubMedGoogle Scholar
  • 37 Maykut M O. Health consequences of acute and chronic marihuana use.  Prog Neuropsychopharmacol Biol Psychiatry. 1985;  9 209-238
    CrossrefPubMedGoogle Scholar
  • 38 Tramèr M R, Carroll C, Campbell F A. et al . Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.  BMJ. 2001;  323 1-8
    CrossrefPubMedGoogle Scholar
  • 39 Bagshaw S M, Hagen N A. Medical efficacy of cannabinoids and marijuana: a comprehensive review of the literature.  J Palliat Care. 2002;  18 111-122
    PubMedGoogle Scholar
  • 40 Buggy D J, Toogood L, Maric S. et al . Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain.  Pain. 2003;  106 169-172
    CrossrefPubMedGoogle Scholar
  • 41 Campbell F A, Tramèr M R, Carroll D. et al . Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review.  Bmj. 2001;  323 13-16
    CrossrefPubMedGoogle Scholar
  • 42 Jain A K, Ryan J R, McMahon F G, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain.  J Clin Pharmacol. 1981;  21 (suppl 8 - 9) S320-S326
    PubMedGoogle Scholar
  • 43 Baker D, Pryce G, Giovannoni G, Thompson A J. The therapeutic potential of cannabis.  Lancet Neurol. 2003;  2 291-298
    CrossrefPubMedGoogle Scholar
  • 44 Fox S H, Kellett M, Moore A P. et al . Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.  Mov Disord. 2002;  17 145-149
    CrossrefPubMedGoogle Scholar
  • 45 Müller-Vahl K R, Prevedel H, Theloe K. et al . Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance.  Neuropsychopharmacology. 2003;  28 384-388
    CrossrefPubMedGoogle Scholar
  • 46 Robson P. Therapeutic aspects of cannabis and cannabinoids.  Br J Psychiatry. 2001;  178 107-115
    CrossrefPubMedGoogle Scholar
  • 47 Hall W, Solowij N. Adverse effects of cannabis.  Lancet. 1998;  352 1611
    CrossrefPubMedGoogle Scholar
  • 48 Macleod J, Oakes R, Copello A. et al . Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies.  Lancet. 2004;  363 1579-1588
    CrossrefPubMedGoogle Scholar
  • 49 Johns A. Psychiatric effects of cannabis.  Br J Psychiatry. 2001;  178 116-122
    CrossrefPubMedGoogle Scholar
  • 50 Smit F, Bolier L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review.  Addiction. 2004;  99 425-430
    CrossrefPubMedGoogle Scholar
  • 51 D'Souza D C, Perry E, MacDougall L. et al . The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis.  Neuropsychopharmacology. 2004;  29 1558-1572
    CrossrefPubMedGoogle Scholar
  • 52 Killestein J, Hoogervorst E L, Reif M. et al . Safety, tolerability, and efficacy of orally administered cannabinoids in MS.  Neurology. 2002;  58 1404-1407
    PubMedGoogle Scholar
  • 53 Greenberg H S, Werness S A, Pugh J E. et al . Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers.  Clin Pharmacol Ther. 1994;  55 324-328
    PubMedGoogle Scholar
  • 54 Fried P A. Prenatal exposure to tobacco and marijuana: effects during pregancy, infancy and early childhood.  Clin Obstet Gynecol. 1993;  36 319-336
    PubMedGoogle Scholar
  • 55 Baker D, Pryce G, Croxford J L. et al . Cannabinoids control spasticity and tremor in a multiple sclerosis model.  Nature. 2000;  404 84-87
    CrossrefPubMedGoogle Scholar
  • 56 Lago E de, Ligresti A, Ortar G. et al . In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake.  Eur J Pharmacol. 2004;  484 249-257
    CrossrefPubMedGoogle Scholar
  • 57 Marzo V Di, Bifulco M, Petrocellis L De. Endocannabinoids and multiple sclerosis: a blessing from the „inner blis”?.  Trends Pharmacol Sci. 2000;  21 195-197
    CrossrefPubMedGoogle Scholar
  • 58 Wirguin I, Mechoulam R, Breuer A. et al . Suppression of experimental autoimmune encephalomyelitis by cannabinoids.  Immunopharmacology. 1994;  28 209-214
    CrossrefPubMedGoogle Scholar
  • 59 Luthra Y K, Rosenkrantz H. Cannabinoids: neurochemical aspects after oral chronic administration to rats.  Toxicol Appl Pharmacol. 1974;  27 158-168
    CrossrefPubMedGoogle Scholar
  • 60 Pryce G, Ahmed Z, Hankey D J. et al . Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.  Brain. 2003;  126 2191-2202
    CrossrefPubMedGoogle Scholar
  • 61 Oleszak E L, Chang J R, Friedman H. et al . Theiler's virus infection: a model for multiple sclerosis.  Clin Microbiol Rev. 2004;  17 174-207
    CrossrefPubMedGoogle Scholar
  • 62 Arevalo-Martin A, Vela J M, Molina-Holgado E. et al . Therapeutic action of cannabinoids in a murine model of multiple sclerosis.  J Neurosci. 2003;  23 2511-2516
    PubMedGoogle Scholar
  • 63 Croxford J L, Miller S D. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212.  J Clin Invest. 2003;  111 1231-1240
    CrossrefPubMedGoogle Scholar
  • 64 Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev 2004 CD004678
    Google Scholar
  • 65 Killestein J, Hoogervorst E L, Reif M. et al . Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis.  J Neuroimmunol. 2003;  137 140-143
    CrossrefPubMedGoogle Scholar
  • 66 Walter L, Stella N. Cannabinoids and neuroinflammation.  Br J Pharmacol. 2004;  141 775-785
    CrossrefPubMedGoogle Scholar
  • 67 Formukong E A, Evans A T, Evans F J. Inhibition of the cataleptic effect of tetrahydrocannabinol by other constituents of Cannabis sativa L.  J Pharm Pharmacol. 1988;  40 132-134
    PubMedGoogle Scholar
  • 68 Petro D J, Ellenberger C Jr. Treatment of human spasticity with delta 9-tetrahydrocannabinol.  J Clin Pharmacol. 1981;  21 413S-416S
    PubMedGoogle Scholar
  • 69 Zajicek J, Fox P, Sanders H. et al . Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.  Lancet. 2003;  362 1517-1526
    CrossrefPubMedGoogle Scholar
  • 70 Wade D T, Robson P, House H. et al . A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.  Clin Rehabil. 2003;  17 21-29
    CrossrefPubMedGoogle Scholar
  • 71 Notcutt W, Price M, Miller R. et al . Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 „N of 1” studies.  Anaesthesia. 2004;  59 440-452
    CrossrefPubMedGoogle Scholar
  • 72 Brenneisen R, Egli A, Elsohly M A. et al . The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients.  Int J Clin Pharmacol Ther. 1996;  34 446-452
    PubMedGoogle Scholar
  • 73 Ungerleider J T, Andyrsiak T, Fairbanks L. et al . Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.  Adv Alcohol Subst Abuse. 1987;  7 39-50
    PubMedGoogle Scholar
  • 74 Martyn C N, Illis L S, Thom J. Nabilone in the treatment of multiple sclerosis.  Lancet. 1995;  345 579
    CrossrefPubMedGoogle Scholar
  • 75 Meinck H M, Schonle P W, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.  J Neurol. 1989;  236 120-122
    PubMedGoogle Scholar
  • 76 Vaney C. A clinical study with a standardized cannabis extract in multiple sclerosis. Berlin; Congress of the International Association for Cannabis as Medicine October 26 - 27, 2001
    Google Scholar
  • 77 Svendsen K B, Jensen T S, Bach F W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.  Bmj. 2004;  329 253
    CrossrefPubMedGoogle Scholar
  • 78 Clifford D B. Tetrahydrocannabinol for tremor in multiple sclerosis.  Ann Neurol. 1983;  13 669-671
    CrossrefPubMedGoogle Scholar
  • 79 Fox P, Bain P G, Glickman S. et al . The effect of cannabis on tremor in patients with multiple sclerosis.  Neurology. 2004;  62 1105-1109
    PubMedGoogle Scholar
  • 80 GW-Pharmaceuticals .http://www.gwpharm.com/ . Accessed 20.5.2004
  • 81 Kauert G. Zur drogen- und medikamentenbedingten Fahruntüchtigkeit aus medizinisch-toxikologischer Sicht.  Deutsches Autorecht. 2000;  69 434-442
    PubMedGoogle Scholar

PD Dr. Stefan Schwarz

Neurologische Universitätsklinik · Klinikum Mannheim

Theodor-Kutzer Ufer 1 - 3

68135 Mannheim

eMail: s.schwarz@neuro.ma.uni-heidelberg.de